Close Menu

targeted sequencing

Early sub-protocol results presented at AACR meeting hint at better outcomes for Mektovi-treated cases with NRAS codon 61 tumor mutations.

Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.

The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.

A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.

Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.

An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.

Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.

The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.

Pages